Table 2.
Cox regression models assessing the potential of clinical and epigenetic variables in the prediction of disease-free survival for 122 patients with BrC and disease-specific survival for 127 patients with BrC.
| Disease-Free Survival | Variable | HR a | CI b (95%) | p Value |
|---|---|---|---|---|
| Univariable | Grade | |||
| G1 | 1 | |||
| G2 c & G3 | 2.054 | 1.029–4.098 | 0.041 | |
| pN Stage | ||||
| N0 d & N1 | 1 | |||
| N2 & N3 | 3.894 | 1.940–7.812 | <0.001 | |
| PSAT1 | ||||
| >P75 e | 1 | |||
| ≤P75 | 3.707 | 1.133–12.127 | 0.030 | |
| Multivariable | Grade | |||
| G1 | 1 | |||
| G2 & G3 | 1.490 | 0.717–3.096 | 0.286 | |
| pN Stage | ||||
| N0 & N1 | 1 | |||
| N2 & N3 | 4.345 | 2.114–8.930 | <0.001 | |
| PSAT1 | ||||
| >P75 e | 1 | |||
| ≤P75 | 3.613 | 1.077–12.123 | 0.038 | |
| Disease-Specific Survival | Variable | HR a | CI b (95%) | p Value |
| Univariable | Grade | |||
| G1 | 1 | |||
| G2 & G3 | 2.725 | 1.155–6.428 | 0.022 | |
| pN Stage | ||||
| N0 & N1 | 1 | |||
| N2 & N3 | 4.061 | 1.814–9.089 | 0.001 | |
| FOXA1 | ||||
| ≤P75 f | 1 | |||
| >P75 | 2.678 | 1.200–5.978 | 0.016 | |
| Multivariable | Grade | |||
| G1 | 1 | |||
| G2 & G3 | 2.005 | 0.082–4.866 | 0.124 | |
| pN Stage | ||||
| N0 & N1 | 1 | |||
| N2 & N3 | 4.855 | 1.981–10.611 | <0.001 | |
| FOXA1 | ||||
| ≤P75 f | 1 | |||
| >P75 | 2.710 | 1.161–6.324 | 0.021 |
a HR—Hazard Ratio; b CI—Confidence Interval; c G—Grade; d N—Regional lymph node status; e P75—Percentile 75 of methylation levels of PSAT1; f P75—Percentile 75 of methylation levels of FOXA1.